Coronavirus (COVID-19) Collection
Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa
The Omicron SARS-CoV-2 variant of concern has been dominant globally since November 2021, with several sublineages causing surges in infections (Iketani et al., 2022; Tegally et al., 2022; Viana et al., 2022). South Africa experienced an initial large BA.1 infection surge from November 2021 to January 2022. BA.1 was then replaced by BA.2 but with no increase in cases numbers, and this was followed by a BA.4/BA.5 infection surge between April and June 2022 (Tegally et al., 2022; Viana et al., 2022).SARS-CoV-2 antibodies persist up to 12 months after natural infection in healthy employees working in non-medical contact-intensive professions
Since the start of the COVID-19 pandemic in early 2020, over 564 million confirmed cases and over 6 million deaths have been reported globally (July 22, 2022) [33]. In the Netherlands (total population: 17.6 million), 8.3 million inhabitants have officially been diagnosed with COVID-19 [34]. This number is an underestimation of the actual number of cases because not all people were tested for severe SARS-CoV-2 infections. Hence, a significant percentage of the population has developed natural immunity against SARS-CoV-2 at some point during the pandemic [2].Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
The Omicron variant (B.1.1.529) of SARS-CoV-2 was first identified in November 2021 (Viana et al., 2022) and has dramatically increased the transmission of COVID-19 worldwide. The COVID-19 vaccine protects against serious disease, hospitalization, and death. However, vaccination does not entirely prevent infection and transmission to others. Massive two-dose vaccination campaigns cannot prevent breakthrough infections caused by the variants (Cele et al., 2022; Kuhlmann et al., 2022). A third dose is recommended to obtain high immunity against the Omicron variant and its subvariants.Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children
Protecting children against COVID-19 is pivotal for controlling virus dissemination and reducing disease incidence. COVID-19 cases and hospitalizations among children and adolescents, firstly driven by the Delta variant and recently by Omicron, have risen sharply, even in countries with high adult vaccination coverage (Delahoy et al., 2021; Elliott et al., 2022). This context has accelerated the clinical trials of anti-SARS-CoV-2 vaccines for children (Ali et al., 2021; Frenck et al., 2021; Han et al., 2021; Wallace et al., 2021; Walter et al., 2021; Xia et al., 2022).Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness
Some patients with COVID-19 pneumonia display clinical and laboratory signs of a hyperinflammatory response, including markedly elevated serum C-reactive protein (CRP) and ferritin levels, followed by rapid respiratory status decompensation and progression to multisystem organ failure. These observations led to the use of varying doses of corticosteroids and targeted anti-cytokine agents, including anakinra, an anti-interleukin (IL)-1 treatment, early in the pandemic.A comprehensive characterization of patients diagnosed with post-COVID-19 condition in Sweden 16 months after the introduction of the International Classification of Diseases Tenth Revision diagnosis code (U09.9): a population-based cohort study
Two years into the COVID-19 pandemic, many questions remain regarding patients with prolonged symptoms after SARS-CoV-2 infection. Although several studies have described post-COVID-19 complications and symptoms in different settings and populations (Ayoubkhani et al., 2021; Blomberg et al., 2021; Havervall et al., 2021; Tran et al., 2022; Westerlind et al., 2021), it is difficult to compare results and draw conclusions due to the substantial heterogeneity between studies (Michelen et al., 2021).COVID-19 and diarrhea: putative mechanisms and management
Since December 2019, COVID-19 has become a global threat to public health and the economy. The main causative agent of this disease, SARS-CoV-2, first appeared in Wuhan city of China and the World Health Organization declared it a global pandemic on March 2020 (Huang et al., 2020). Along with a great toll on economic growth and interruption of the general lifestyle of people, COVID-19 has become one of the major public health crises infecting around 533 million people till June 12, 2022, taking more than 6.3 million lives reported from 226 countries (World Health Organization, 2022).Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infection
Vaccination represents the most important strategy to prevent infection, severe complications, and death caused by SARS-CoV-2 (Feikin et al., 2022). SARS-CoV-2 vaccination may also reduce the risk of post-acute sequelae of SARS-CoV-2 infection (PASC) (Antonelli et al., 2022; Azzolini et al., 2022; Kuodi et al., 2022), but conflicting results have been presented (Taquet et al., 2022). We aimed to describe self-reported PASC symptoms, including memory and concentration problems, changes in smell and taste, fatigue, and dyspnea, persisting 3-15 months after a positive test in SARS-CoV-2 unvaccinated and vaccinated participants with a breakthrough infection.Reduction in severity and mortality in COVID-19 patients owing to heterologous third and fourth-dose vaccines during the periods of delta and omicron predominance in Thailand
As of July 30, 2022, the COVID-19 pandemic caused by SARS-CoV-2 has led to more than 582 million confirmed cases globally with more than 170 million in Asia and almost 5 million in Thailand alone (Mathieu et al., 2022). This has unfortunately resulted in almost 6.4 million deaths worldwide, 1.5 million deaths across Asia, and over 31,000 deaths in Thailand (Mathieu et al., 2022). While public health measures like wearing masks, social distancing, and appropriate hygiene measures were able to limit the spread of SARS-CoV-2, the rapid development and deployment of vaccines were responsible for reducing the clinical impact of COVID-19 substantially (Doroshenko, 2021; Moore et al.Comparative analysis of elderly hospitalized patients with COVID-19 or influenza A H1N1 virus infections
The SARS-CoV-2, SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), and influenza A viruses are major pathogens that damage the respiratory system and can produce outbreaks of SARS, MERS, COVID‐19, and influenza A H1N1 virus pneumonia, respectively. SARS-CoV-2, SARS-CoV, and Middle East respiratory syndrome coronavirus are from the same genus and share many virological and epidemiological similarities. However, COVID-19 shows more similarities with influenza A H1N1 virus infections in the pattern and scale of spread than with SARS or MERS.A large series of molecular and serological specimens to evaluate mother-to-child SARS-CoV-2 transmission: a prospective study from the Italian Obstetric Surveillance System
The ongoing SARS-CoV-2 pandemic is characterized by multiple epidemic waves associated with different viral strains with diverse transmissibility and lethality. The previous highly pathogenic SARS-CoV-1 and middle east respiratory syndrome coronavirus were associated with poor obstetric outcomes (Schwartz and Graham, 2020). Given the importance of understanding COVID-19’s impact on pregnant women, fetuses, and newborns, the Italian Obstetric Surveillance System (ItOSS), coordinated by the Istituto Superiore di Sanità (Italian National Institute of Health-ISS), launched a nationwide population-based, prospective cohort study aimed at analyzing cases of SARS-CoV-2 infection in pregnant women with the purpose to provide useful indications to guide decision makers and support clinical practice (Donati et al.Viable SARS-CoV-2 detected in the air of hospital rooms of patients with COVID-19 with an early infection
COVID-19 is caused by the highly transmissible SARS-CoV-2. Understanding the role of surface and air contamination near patients with COVID-19 in the transmission of SARS-CoV-2 is essential to ensure the prevention of SARS-CoV-2 transmission. SARS-CoV-2 RNA has been detected on surfaces and in the air in hospitals (Dinoi et al., 2022; Gonçalves et al., 2021). However, only a few studies have recovered viable SARS-CoV-2 from the air collected near the patients with COVID-19 (Lednicky et al., 2020, 2021; Vass et al.High prevalence of SARS-CoV-2 antibodies in pregnant women after the second wave of infections in the inner-city of Johannesburg, Gauteng Province, South Africa
In South Africa, by the end of the second COVID-19 wave in early February 2021, which driven largely by the Beta variant (501Y.V2), almost 1.5 million COVID-19 cases and 47,000 deaths were recorded (National Institute for Communicable Diseases [NICD], 2021). By the end of September 2021, as South Africa exited the third wave, which was dominated by the Delta variant, just over 2.9 million diagnosed cases and more than 87,000 COVID-19-related deaths were reported (NDoH, 2021). Of these, more than one-third of cases and a quarter of deaths were from the Gauteng Province, the most densely populated province in South Africa, with the City of Johannesburg accounting for almost one-third of diagnosed cases (NDoH, 2021, NICD, 2021).Could nucleocapsid be a next-generation COVID-19 vaccine candidate – author's reply
This is in response to a letter to the editor by Saldivar-Espinoza et al. (2022) commenting on a short perspective that we wrote in the September 2022 issue of the International Journal of Infectious Disease entitled, “Nucleocapsid as a next-generation COVID-19 vaccine candidate” (Oronsky et al., 2022). The main point of this perspective was that nucleocapsid (N), being highly conserved among coronaviruses (CoVs), less mutable than spike (S), and strongly immunogenic, especially for T cells (Lineburg et al.Could nucleocapsid be a next-generation COVID-19 vaccine candidate?
We have read with interest the article by Oronsky et al. (2022) about including the SARS-CoV-2 nucleocapsid (N) protein in future COVID-19 vaccines. One of the main reasons for this suggestion is that the N gene is much less vulnerable to mutation and may provide stronger immunity to novel viral variants. Although when the proteins of SARS-CoV-2 and SARS-CoV are compared, the N protein is more conserved than the spike (S) protein (Dutta et al., 2020); the current data we have analyzed about SARS-CoV-2 mutations show that the N gene is one of the most mutated genes (Figure 1).SARS-CoV-2 genomic surveillance in Malaysia: displacement of B.1.617.2 with AY lineages as the dominant Delta variants and the introduction of Omicron during the fourth epidemic wave
Since the declaration of COVID-19 as a pandemic by the World Health Organization in March 2020, COVID-19 continues to be an important health problem worldwide (Gao et al., 2021). The index case of COVID-19 was detected on December 1, 2019, in Wuhan City, Hubei Province, China (Helmy et al., 2020; Valencia, 2020). As of January 2022, there were 380 million COVID-19 cases, with a mortality rate of 1.5% (Worldometer, 2022). COVID-19 is caused by SARS-CoV-2, an enveloped, nonsegmented, positive-sense RNA β-coronavirus (Zhou et al.Clinical outcomes associated with Mu variant infection during the third epidemic peak of COVID-19 in Colombia
By July 2022, four COVID-19 epidemic peaks and 210 lineages have been registered in Colombia, including several variants of interest and concern (INS, 2022). However, a higher number of cases and deaths occurred during the third epidemic peak, when the B.1.621 (Mu) variant was associated with 50% of the cases in the country (Álvarez-Díaz et al., 2022a). Although several factors in the clinical history of patients with COVID-19 have been associated with a severe or fatal outcome, including comorbidities, age, and smoking history (Zhang et al.Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study
Since the COVID-19 pandemic appearance, a global effort has been made to develop effective vaccines to stem SARS-CoV-2 infection through the induction of a coordinated B and T cell immune response (Agrati et al., 2021; Aiello et al., 2022a; Sette and Crotty, 2021, 2022). Humoral immunity consists of antibodies binding the SARS-CoV-2 spike (S) protein that neutralizes the virus, whereas cellular immunity includes virus-specific B and T cells, which provide long-term memory and promptly expand following re-exposure to antigens (Sette and Crotty, 2021, 2022).Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study
The ongoing COVID-19 pandemic caused by SARS-CoV-2 has devastated countries. The race to find adequate therapies is ongoing, but significant progress has been made since 2019. Our understanding of COVID-19 pathogenesis revealed the need for targeting the dysregulated immune response. The term cytokine storm first appeared 30 years ago, describing a potentially life-threatening condition triggered by various pathogens, hematologic and immunological disorders, and is characterized by peripheral hyperactivation of T-lymphocytes, resulting in elevated cytokines levels, systemic inflammation, and end-organ damage (Chatenoud et al.High-dose corticosteroids in patients hospitalized for COVID-19 pneumonia: an observational study of comparative effectiveness
The optimal dose of corticosteroids in the treatment of SARS-CoV-2 infection is uncertain, particularly among patients with severe respiratory impairment (The WHO Rapid Evidence Appraisal for COVID-19 Therapies [REACT] Working Group, 2020), and practice remains varied. Recent randomized controlled trials (RCTs) that compared high (12 mg) to low (6 mg) doses of dexamethasone in patients hospitalized for severe COVID-19 pneumonia found no difference in mortality (Bouadma et al., 2022) or were inconclusive (COVID STEROID 2 Trial Group et al.Enhanced vitamin K expenditure as a major contributor to vitamin K deficiency in COVID-19
In December 2019, the acute respiratory disease COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), made its appearance in Wuhan, China (Huang et al., 2020). Several studies trying to clarify the COVID-19 pathogenesis or investigating different remedies have been conducted and reviewed (Oliaei et al., 2021; SeyedAlinaghi et al., 2021); however, the need to elucidate the disease pathways of this poignant disease remains. Severe vitamin K deficiency has been demonstrated in hospitalized COVID-19 patients and consistently been associated with worse clinical outcome (Desai et al.Transmission dynamics of SARS-CoV-2 Omicron variant infections in Hangzhou, Zhejiang, China, January-February 2022
From the end of 2020, multiple variants of concern have emerged during the COVID-19 pandemic. Most recently, the Omicron variant has become dominant worldwide over other strains, with the potential for the emergence of other new variants or subvariants in the future. The Omicron variants have demonstrated increasing transmissibility and therefore are more challenging to control (Kraemer et al., 2021; World Health Organization, 2022). In general, increased transmissibility for a variant indicates an increased transmission strength, a higher transmission speed, or both.Workup of cerebral involvement in patients with COVID-19 – authors’ reply
We thank Scorza et al. for their comments on our article (Chen et al., 2022) discussing the new S protein mutation of SARS-CoV-2 and its potential effects on immune regulation, associated with the apparent increase in the incidence of severe neurological symptoms in Taiwanese pediatric patients.Workup for cerebral involvement in COVID-19 requires cerebral imaging, electroencephalography, and cerebrospinal fluid studies
We read with interest the article by Chen et al. (2022) concerning five pediatric patients with severe neurological complications of acute SARS-CoV-2 infection. It was concluded that a new mutation in the spike protein of the Omicron BA.2.3.7 variant may be responsible for the sudden increase in neurological complications of COVID-19 (Chen et al., 2022). The study is appealing but raises concerns.Effect of corticosteroids in patients with COVID-19: a Bayesian network meta-analysis
As of August 5, 2022, nearly 600 million persons have been diagnosed with COVID-19, and more than 6 million individuals have died because of this disease (World Health Organization, 2022). Evidence has shown that a severely dysregulated immune response plays a critical role in patients with COVID-19 (Prete et al., 2020; Vabret et al., 2020).SARS-CoV-2 vertical transmission in a twin-pregnant woman: a case report
SARS-CoV-2 represents one of the most threatening infections in the last century, affecting millions of people worldwide (World Health Organization, 2020) ( covid19.who.int ).Testing for COVID-19 during an outbreak within a large UK prison: an evaluation of mass testing to inform outbreak control
Since the first cases were identified in 2019, COVID-19 has caused a global pandemic which has disrupted economies and caused significant morbidity and mortality. With COVID-19 predominantly spread through aerosols and those in close contact at the highest risk, concern was voiced that institutions such as prisons would be at risk of large outbreaks (Burki, 2020), exacerbated by overcrowding and poor health of imprisoned people (Davies et al., 2020; Fazel et al., 2001). Coupled with difficulties implementing basic infection prevention and control measures because of limited access to handwashing points, crowded conditions, little control over social distancing, and movement of both staff and people, it was expected that prisons would become a hotspot for COVID-19 outbreaks (Burki, 2020).Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis
The transmission of SARS-CoV-2 has led to the ongoing global COVID-19 pandemic. By August 19, 2022, more than 590 million have had confirmed COVID-19 and more than 6 million have died worldwide (World Health Organization, 2022). The morbidity and mortality from COVID-19 and its complications and large-scale economic disruption have prompted an unprecedented pace in highly efficacious vaccine development (Berlin et al., 2020; Merad et al., 2022). As of August 19, 2022, a total of 12.4 billion vaccine doses have been administered (World Health Organization, 2022), and the most widely used are messenger RNA (mRNA) vaccines, including BNT162b2 (Pfizer-BioNTech, New York, NY, USA-Mainz, Germany) and mRNA-1273 (Moderna, Cambridge, MA, USA) vaccines and viral vector vaccines, such as Ad26.CoV2.S (Johnson & Johnson, New Brunswick, NJ, USA), ChAdOx (AstraZeneca, Cambridge, UK), Sputnik V (Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia), and the traditional inactivated virus alum-adjuvanted candidate vaccine CoronaVac (Sinovac, Beijing, China) (Piccaluga et al.Effects of COVID-19-targeted nonpharmaceutical interventions on children's respiratory admissions in China: a national multicenter time series study
COVID-19 has exerted a profound influence on everyday life and the healthcare system worldwide. Since the outburst of COVID-19 in Wuhan city, China, in January 2020, a series of nonpharmaceutical interventions (NPIs) have been conducted nationwide. The NPIs refer to the combination of mask-wearing, handwashing, and social distancing, such as closing schools and public places, quarantining infected patients and close contacts, and travel restrictions (Fricke et al., 2021; Zhang et al., 2021a). These measures have effectively curbed the large-scale spread of the epidemic, keeping the number of people infected with COVID-19 in China under control (Tang and Abbasi, 2021).Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase
With fluctuating rates of transmission of SARS-CoV-2, neutralizing monoclonal antibody (mAb) products such as sotrovimab for outpatients who have recently tested positive for SARS-CoV-2 have been critical, evidence-based treatments to mitigate the impact of COVID-19 surges on the health care system and improve COVID-19 outcomes among high-risk individuals (Aggarwal et al., 2022; Centers for Disease Control and Prevention, 2021; Ganesh et al., 2021; Huang et al., 2022; Jarrett et al., 2021; O'Horo et al.Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
Vaccination against infection with SARS-CoV-2 in the general population of Japan began on April 12, 2021, and booster vaccination (the third dose) began on December 1, 2021. The Alpha (B.1.1.7) variant was gradually replaced by the Delta (B.1.617.2) variant beginning in June 2021, and the Delta variant accounted for approximately 80% of infections in Japan in August 2021 (National Institute of Infectious Diseases, 2021). The Delta variant predominated until the Omicron (B.1.1.529) variant surged in January 2022 (National Institute of Infectious Diseases, 2022; Ode et al.Characteristics of long-COVID among older adults: a cross-sectional study
Long-COVID has been reported to affect a substantial portion of survivors of COVID-19, including those who experienced mild acute disease (Carter et al., 2022; Chen et al., 2022; Yan et al., 2021). In many of the cases, the affected individuals experience debilitating symptoms that affect their physical and cognitive function, impairing their quality of life. Recent longer-term follow-up studies show that many individuals do not experience full recovery even 1 year after infection (PHOSP-COVID Collaborative Group, 2022; Zhang et al.Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial)
COVID-19 is caused by the SARS-CoV-2 infection and caused the pandemic with high mortality. Household transmission is the most common transmission source in the countries with COVID-19 outbreaks (Pollán et al., 2020). In England, the secondary infection rate is 4-6.4 per 100 households (Hall et al., 2021). The secondary attack rate (SAR) in other countries is 16.3-53% (Grijalva et al., 2020; Li et al., 2020; Singanayagam et al., 2022). The systematic review demonstrated an average of 17% secondary infections (4-45%), and the SAR was 31.1% during the B.1.617.2 outbreak, whereas the high transmissibility in Thai households was 56% (Madewell et al.A global epidemiological analysis of COVID-19 vaccine types and clinical outcomes
SARS-CoV-2 has led to more than 275 million cases of disease and 5 million deaths worldwide. COVID-19 vaccines deployed in many parts of the world since early 2021, albeit unevenly, have been shown to protect vaccinees against disease and mortality (Al Kaabi et al., 2021; Butt et al., 2021; Cheng et al., 2021; Fadlyana et al., 2021; Jara et al., 2021; Li et al., 2021; Rotshild et al., 2021; Sadoff et al., 2021; Tanriover et al., 2021). However, at the time this study was conducted, there was conflicting evidence about the quality and potency of immune protection afforded by COVID-19 messenger RNA (mRNA)-based and adenovirus-vectored vaccines (ADVV) compared with inactivated virus vaccines (IVV) against SARS-CoV-2 pre-Omicron variants (Cheng et al.Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
Several monoclonal antibodies against SARS-CoV-2 have been developed for the treatment of COVID-19 (Miguez-Rey et al., 2022). One of these is sotrovimab, which significantly reduced the risk of COVID-19 hospitalization and death due to infection with pre-Omicron SARS-CoV-2 variants in a randomized clinical trial (Gupta et al., 2021). The United States Food and Drug Administration (FDA) issued an emergency authorization to permit the use of sotrovimab for the treatment of mild-to-moderate COVID-19 in patients at high risk of progression to severe COVID-19 (US Food and Drug Administration, 2022).Diagnostic accuracy of a novel SARS CoV-2 rapid antigen test and usefulness of specimens collected from the anterior nasal cavity
Many health care providers are hopeful regarding COVID-19 testing programs that use accurate rapid antigen tests to reduce the burden on the health care system through early diagnosis of infection (Chen et al., 2021). If performed appropriately, these testing programs can support rapid and accurate decisions with respect to the isolation and treatment of patients with COVID-19 (World Health Organization, 2020a). Currently, various antigen-detecting rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 are commercially available (Brümmer et al.Non-severe COVID-19 complicated by cytotoxic lesions of the corpus callosum (mild encephalitis/encephalopathy with a reversible splenial lesion): a case report and literature review
Coronavirus disease 2019- (COVID-19-) associated cytotoxic lesions of the corpus callosum (CLOCCs) have been reported as a rare neurological abnormality in severe cases. Here, a case of CLOCCs in the early stages of mild COVID-19 infection during the Omicron BA.1 epidemic is reported along with a literature review.Spike-specific T-cell responses in patients with COVID-19 successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2
Passive immunization by administering neutralizing monoclonal antibodies (moAbs) against SARS-CoV-2 is an effective therapeutic strategy in reducing both hospitalization and death related to COVID-19 (Dougan et al., 2021; Gupta et al., 2021; Montgomery et al., 2022; Weinreich et al., 2021). To date, the Food and Drug Administration has approved more than 30 SARS-CoV-2 moAbs for clinical trials. In Italy, five moAbs have been introduced into clinical practice for early treatment of COVID-19 following clearance by the Italian Drug Agency (AIFA) (AIFA, 2022).Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021)
COVID-19, caused by SARS-CoV-2, was declared a public health emergency of international concern on January 30, 2020. As of June 12, 2022, there have been 533,160,628 confirmed cases worldwide, including over 6 million deaths (WHO, 2022).Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [ComirnatyⓇ])
The most common adverse reactions of the Pfizer-BioNTech BNT162b2 messenger RNA (mRNA) COVID-19 vaccine (ComirnatyⓇ) were local reactions at the injection site, fatigue, headache, muscle pain, chills, joint pain, and fever (Thomas et al., 2021). A serious allergic reaction involved anaphylaxis, but the incidence was very low, and other allergic reactions have been uncertain. We herein report a patient who developed acute asthma exacerbation after receiving the third dose of the BNT16b2 vaccine, who was considered likely to have been sensitized to the BNT16b2 vaccine during repeated vaccination.SARS-CoV-2 vertical transmission during the first trimester of pregnancy in asymptomatic women
It is now well established that in utero vertical SARS-CoV-2 transmission can occur during the late third trimester (Fenizia et al., 2020; Vivanti et al., 2020). A systematic review of the cases reported in the literature estimated that of all the newborns who were SARS-CoV-2-positive, congenital transmission ranged from 5.7 to possibly 12.2% (Raschetti et al., 2020). As specimens are easily accessible postpartum, many studies focused on the late third trimester to assess the risk of vertical transmission.The first case of meningitis associated with SARS-CoV-2 BA.2 variant infection with persistent viremia
Neurological symptoms of COVID-19 are highly frequent and disabling (Wan et al., 2021). Severe neurological disorders such as encephalitis, meningitis, Guillain-Barré syndrome, and vascular events have been described in anecdotal reports or in case series. Here, we describe the first case of a female patient infected with the SARS-CoV-2 BA.2 Omicron variant of concern (VoC) meningitis with newly diagnosed central demyelinating disease.Azithromycin use and outcomes in patients with COVID-19: an observational real-world study
COVID-19, caused by the new SARS-CoV-2, continues to be widespread, with nearly 600 million cases and >6 million deaths worldwide as of August 29, 2022 (World Health Organization, 2022). Most patients with COVID-19 have flu-like syndrome with a variety of mild symptoms including rhinitis, pharyngitis, cough, and fever. However, some patients experience a more life-threatening disease characterized by respiratory failure, a proinflammatory state, and arterial thromboembolism, which may require hospitalization and intensive care unit (ICU) admission (Bonaventura et al.Critical pediatric neurological illness associated with COVID-19 (Omicron BA.2.3.7 variant) infection in Taiwan: immunological assessment and viral genome analysis in tertiary medical center
Since the COVID-19 pandemic outbreak, people all around the world have continued to fight it (Jian et al., 2022). However, as the virus evolves, more variants of concern have been reported (Chung et al., 2022). Patients with COVID-19 infection have also experienced neurological symptoms during the course of the infection (Nordvig et al., 2021). However, severe neurological complications have tended to be more common in children recently (Dilber et al., 2021; Valderas et al., 2022).Simultaneous co-infection with Omicron (B.1.1.529) and Delta (21A/478K.V1) SARS-CoV-2 variants confirmed by whole genome sequencing
The national data of the epidemiological survey of COVID-19 variants carried out in France has shown a predominance of the Delta variant (21A/478K.V1) since June 29, 2021 (Santé publique France 2021). Since the SARS-CoV-2 Omicron variant (B.1.1.529) was first reported (WHO, 2021), it has rapidly spread worldwide. Preliminary evidence suggests an increased risk of reinfection with this variant compared with other variants of concern (VOCs) (WHO, 2021) but no simultaneous co-infection. We described herein a case of SARS-CoV-2 Omicron and Delta VOCs co-infection, confirmed by whole genome sequencing (WGS).Monitoring of SARS-CoV-2 circulation using saliva testing in school children in Rome, Italy
Since October 2020, the identification of suspected cases and contact tracing in the Lazio region have been supported by active surveillance initiatives in schools through antigen tests performed mainly on saliva (Bordi et al., 2021; Iwasaki et al., 2020). For the school year 2021-2022, the National Plan implemented the “Plan for monitoring of the circulation of SARS-CoV-2 in primary and lower secondary schools”. The Laboratory of Virology of the National Institute for Infectious Diseases “L. Spallanzani” was involved in the screening of saliva samples collected from students belonging to the local surveillance unit (ASL) RM3 of Rome.Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?
COVID-19 first emerged in Wuhan, China, in December 2019, resulting in a rapid spread in the outbreak of pneumonia. The pandemic has affected millions of individuals and claimed more than 6 million lives worldwide, leading to massive health, social, and economic issues (Cascella et al., 2022). Patients with COVID-19 often experience fatigue, fever, cough, pneumonia, and acute respiratory distress syndrome at the advanced stages (Shirani et al., 2020). Except for respiratory symptoms, COVID-19 might be directly or indirectly linked to severe cardiovascular complications, such as palpitation, chest pain, and acute cardiovascular injury (Driggin et al.SARS-CoV-2 dual infection with Delta and Omicron variants in an immunocompetent host: a case report
Dual infections (those caused by two different viral variants) have been described with RNA viruses but are rare among respiratory viral infections (Calistri et al., 2011; Myers et al., 2011). For SARS-CoV-2, few cases of dual infection have been reported, despite an extremely high number of persons being infected worldwide (Francisco et al., 2021; Pedro et al., 2021; Roychoudhury et al., 2022; Samoilov et al., 2021; Vankeerberghen et al., 2021). However, pinning down these cases is complicated; they can be identified with higher probability during the transition from dominance of one SARS-CoV-2 variant of concern to another in the population.Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
Since the outbreak of the COVID-19 pandemic, the highest death rates have been consistently recorded among people older than 65 years old (World Health Organization, 2022). Although multiple countries prioritized older adults in the national vaccination strategies against SARS-CoV-2 (Our World in Data, 2022), an increase in breakthrough COVID-19 infections was found among older adults (Haas et al., 2021). Moreover, several studies identified older age as a substantial barrier for vaccine uptake due to lack of trust, which could constrain vaccination coverage of this vulnerable population (Jantzen et al., 2022; Siu et al., 2022; Tan et al., 2022).Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers
Vaccination with Food and Drug Administration (FDA)–approved/authorized COVID-19 vaccines is imperative to control the ongoing pandemic. Several studies have demonstrated robust similar or higher early anti-spike (anti-S), anti-S-receptor binding domain (RBD), and neutralizing antibody (nAb) responses after primary vaccination with mRNA-1273 compared with BNT162b2 and higher responses with both mRNA vaccines compared with Ad26.COV2.S (Collier et al., 2021; Debes et al., 2021; Naranbhai et al., 2022; Richards et al.
